Login to Your Account



Anacor pivotal trials test AN2728 in atopic dermatitis

By Michael Fitzhugh
Staff Writer

Tuesday, April 1, 2014
Anacor Pharmaceuticals Inc. has enrolled the first patient in a pair of pivotal phase III trials of AN2728, its lead topical anti-inflammatory candidate for the treatment of atopic dermatitis and psoriasis that could eventually offer a new alternative to corticosteroids and topical immunomodulator therapies for the common skin conditions.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription